# Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

> **NCT04910100** · PHASE2 · COMPLETED · sponsor: **Betaliq, Inc.** · enrollment: 226 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Nebivolol Ophthalmic Suspension 1 Percent
- **DRUG:** Nebivolol Ophthalmic Suspension 0.5 Percent
- **DRUG:** Timolol Ophthalmic Suspension 0.5 Percent
- **DRUG:** Timolol Ophthalmic Solution 0.5 Percent

## Key facts

- **NCT ID:** NCT04910100
- **Lead sponsor:** Betaliq, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-15
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-04-29
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910100, "Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04910100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*